Immunization

The European Medicines Agency determined that the benefits of Johnson & Johnson’s COVID-19 vaccine outweigh the risks. The vaccine is still paused in the United States.

What workflow is best for your pharmacy team?

A new survey conducted by NCPA showed that many independents are serving vulnerable populations but are not receiving adequate supplies of COVID-19 vaccine.

Authors of a paper published in Neurology suggest that a case of Guillain-Barré Syndrome reported in a COVID-19 vaccine trial may have been a coincidence.

The CDC and FDA will further investigate the reports of blood clots following administration of the vaccine.

Store owners offer tips for supplying and giving shots.

Store owners offer tips for supplying and giving shots.

A session at the American Pharmacists Association 2021 Annual Meeting and Exposition addressed recent immunization practice changes.

In part 2 of our interview, Rich Tremonte of AmerisourceBergen discusses distribution highlights, inspiring efforts from pharmacists, and the future of COVID-19 vaccination.

The FDA has made revisions to the emergency use authorization for the Moderna COVID-19 vaccine.

Store owners offer tips for supplying and giving shots.

The vaccine is 91.3% effective against COVID-19 for up to 6 months after the second dose, according to an analysis of data collected through March 13.

Pfizer/BioNTech released data on their COVID-19 vaccine that indicates high efficacy in children aged 12 to 15 years.

A retrospectively analysis assessed the effect of a remote vaccination review process on vaccination status during the COVID-19 pandemic.

A team of researchers have released study results that show the Moderna and Pfizer vaccines are indeed safe and effective for this population.

The updated analyses of the AZD1222 COVID-19 vaccine will be submitted to the FDA for emergency use authorization, according to AstraZeneca.

A recent study looked at the role of the influenza vaccine in COVID-19 susceptibility and severity

AstraZeneca responded to the concerns by promising to release the most up-to-date data within 48 hours.

Increasing reports have surfaced of vaccine recipients experiencing delayed cutaneous side effects after receiving the first dose.

AstraZeneca is preparing to submit its COVID-19 vaccine data to the FDA for emergency use authorization in the coming weeks.

The CDC reported data demonstrating high adherence to COVID-19 vaccine doses among recipients.

Germany, Spain, Ireland, and France, among other EU countries, have decided to temporarily suspend the AstraZeneca COVID-19 vaccine amid reports of serious cases of blood clots.